# The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

> **NCT06717295** · — · RECRUITING · sponsor: **Javier Toledo** · enrollment: 6000 (estimated)

## Conditions studied

- Brest Cancer
- Lung Cancer (NSCLC)
- Pancreatic Cancer, Adult
- Prostate Cancers
- Ovarian Cancer
- Colorectal Cancer
- Glioblastoma (GBM)
- Liver Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** DiNanoQ: A multi-cancer early detection (MCED) blood test
- **OTHER:** DiNanoTrack: Therapeutic Response Monitoring Blood Test

## Key facts

- **NCT ID:** NCT06717295
- **Lead sponsor:** Javier Toledo
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717295, "The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06717295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*